Artificial Intelligence in Finance

at

Hong Kong University of Science and Technology

# WE PREVENT WHAT OTHERS CAN'T FIND

THE DEEP LEARNING CYBER SECURITY PLATFORM FOR ZERO TIME PREVENTION

Deep Instinct is changing the way we look at cybersecurity by harnessing the power of Deep Learning to prevent threats in zero time.

REQUEST A DEMO   HOW IT WORKS

WHAT'S NEW AT DEEP INSTINCT

X-37 Announces $14.5 Million Series A

November 14, 2019 09:00 AM Eastern Standard Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--X-37, LLC, an artificial intelligence-enabled drug discovery company, announced today that it has closed a $14.5 million Series A financing. The funding round was led by DCVC Bio and was joined by Alpha Intelligence Capital and Hemi Ventures. The Series A funding will be used to expand the number of drug development programs at X-37 and to advance identified drug leads through laboratory and preclinical testing, with the goal of beginning human clinical trials by 2022. X-37's development programs encompass novel therapeutics modulating important drug targets to address unmet clinical needs, including ZAP-70 for autoimmune disease, PIM3 and SHP2 for cancer, and Factor XIIa for anticoagulation.

"With this financing, we have the ability to progress multiple discovery and development programs. Our investors have been a huge help in the genesis of X-37, and we look forward to working closely with them going forward."

Tweet this

X-37 was cofounded by Atomwise Inc. and a team of experienced pharmaceutical developers from Velocity Pharmaceutical Development. In addition to the above development programs, the team at X-37 will identify additional high-value drug targets, generate novel drug leads against these targets using Atomwise's world-class AI platform for structure-based drug design, and develop each of these drug programs to a medically-relevant inflection point, where it can be acquired by or partnered with a major pharmaceutical company to be brought to market.

X-37 makes use of an LLC structure permitting each drug development program to be housed in a separate virtual company under the parent LLC. This structure is tax efficient and flexible, in that it allows X-37 to divest individual drug development programs, while maintaining the parent company and team. X-37 began operation in 2018 and has already generated promising novel hit molecules against several targets of high interest to the pharmaceutical industry.

"We are thrilled with the progress we have made to date and we are looking forward to moving a set of important new drugs into development," said David Collier, M.D., CEO and cofounder of X-37. "With this financing, we have the ability to progress multiple discovery and development programs. Our investors have been a huge help in the genesis of X-37, and we look forward to working closely with them going forward."

"X-37 represents an opportunity to bring new drugs to market very quickly, for challenging targets that have repeatedly stumped pharma and are in dire need of advancement," said Abraham Heifets, CEO and Founder of Atomwise, Inc. "We're thrilled to work alongside industry veterans who have a track record of efficiently delivering drug after drug for the past 25 years."

"We are very pleased to be investors in X-37," said Kiersten Stead of DCVC Bio. "We have watched with great excitement as Atomwise has refined its deep neural network and chemistry expertise. We identified the team of drug developers at Velocity Pharmaceutical

X-37, LLC

Release Summary

Cofounded by Atomwise and Velocity Pharmaceutical Development, X-37 combines a world-class AI platform and experienced pharmaceutical developers.

投中网 > 业界动态 > 正文

央行数字货币研究所与商汤科技签署合作协议 开启人工智能领域多项深度合作

投中网　|　投中网

2020-04-27 10:39:39

> 双方将共同建立联合攻关创新体，以应用场景为导向，共同开展人工智能技术在金融场景中的应用开发，加速推进金融领域的人工智能创新研究。

近日，中国人民银行数字货币研究所与商汤科技签署合作协议，双方将围绕金融科技领域的人工智能创新研究和应用开发等方面展开合作，充分发挥各自优势，加快人工智能前沿技术在金融领域的创新和落地。

双方将共同建立联合攻关创新体，以应用场景为导向，共同开展人工智能技术在金融场景中的应用开发，加速推进金融领域的人工智能创新研究。

数字货币研究所是央行旗下专门从事法定数字货币研发和金融科技技术、应用的创新机构。作为中国最大的人工智能技术解决方案提供商，商汤科技将以此合作为契机，放大"智能视觉"国家新一代人工智能开放创新平台优势，与数研所共同探索长期、深入的合作空间，进一步推动AI视觉领域前沿技术在金融领域的深度研究与应用，加快金融行业业务的智能化创新，并最终提升金融机构风险管控和业务运营能力，为金融行业发展提供更强推动力。

网站编辑：　王满华

👍
0

相关文章

央行2020年度招聘：数字货币研究所欲招聘6人

比特币疯狂大跌，听矿友讲述如何一步步入坑挖矿

黄奇帆：中国央行或成为世界首个推出数字货币的央行

本周热文

TOP1

独家 | 李国庆今日带人去抢当当公章? 楼下现警车 李国庆回应：已接管当当

2

沈南鹏对话苏世民：走出疫情，中国将是全球最强的增长型国家

3天前

3

传中金首席经济学家梁红即将离职，下一站或是高瓴资本合伙人

Beyond the Classroom

Topics of Interest
(n = 34)

Topic	Percentage
CV Writing & Interview Preparation	76%
Company Research: Bloomberg, McKinsey Insights, Zero2IPO	47%
LinkedIn & Networking	47%
Industry Primer: FinTech & VC/PE	35%
Industry Primer: Investment Banking	32%
PowerPoint Creation	24%
Certifications (CFA, CPA, FRM, CAIA…)	18%
Industry Primer: Management Consulting	15%